The therapeutic potential of interleukin 10 in infection and inflammation

Archivum Immunologiae et Therapiae Experimentalis

Volumn 48, Issue 6, 2000, Pages 529-538

  Kumar, Ashok ^a   Creery, W David ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

HIV; IL 10; IL 10 knock out mice; Infectious diseases; Sepsis

Indexed keywords

INTERLEUKIN 10;

ANIMAL; ENDOTOXEMIA; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFLAMMATION; MOUSE; MOUSE MUTANT; PHASE 1 CLINICAL TRIAL; REVIEW; SEPSIS; TRANSGENIC MOUSE;

ANIMALS; CLINICAL TRIALS, PHASE I; ENDOTOXEMIA; HIV INFECTIONS; HUMANS; INFECTION; INFLAMMATION; INTERLEUKIN-10; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SEPSIS;

EID: 0034569171     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. AGEMATSU K., NAGUMO H., OGUCHI Y., NAKAZAWA T., FUKUSHIMA K., YASUI K., ITO S., KOBATA T., MORIMOTO C. and KOMIYAMA A. (1998): Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood, 91, 173-180.
2. AHRENDT L. D., WITEK J., DEAN L. M., SIGLER A. J., BLUMBERG E. A., WOOD C. A., MOLAVI A., ASTORIDIS P., FRIME M. B., CUTLER D. L., GOLD M. J. and FUCHS A. C. (1999): A phase I study of interleukin-10 (IL-10) in HIV-infected individuals. Abstract no 613. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, 195.
3. AKDIS C. A. and BLASER K. (1999): IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J., 13, 603-609.
4. AKRIDGE R. E., OYAFUSO L. K. and REED S. G. (1994): IL-10 is induced during HIV-1 infection and is capable of decreasing viral replication in human macrophages. J. Immunol., 153, 5782-5789.
5. ANGEL J. B., JACOBSON M., SKOLNIK P. R., GIORDANO M., SHAPIRO L., LEBEAUT A., GREAVES W. and FUCHS A. C. (1999): A randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 (rhuIL-10) in HIV-infected subjects with CD4+ T cell counts >200 cells/μ L. Abstract no 355. Abstracts of the IDSA 37th Annual Meeting, 1024.
6. ANGEL J. B., SAGET B. M., WANG M. Z., WANG A., DINARELLO C. A. and SKOLNIK P. R. (1995): Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. J. Interferon Cytokine Res., 15, 575-584.
7. BARCOVA M., KACANI L., SPETH C. and DIERICH, M. P. (1998): gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production. J. Infect. Dis., 177, 905-913.
8. BARON S., TYRING S. K., FLEISCHMANN W. R. J., COPPENHAVER D. H., NIESEL D. W., KLIMPEL G. R., STANTON G. J. and HUGHES T. K. (1991): The interferons. Mechanisms of action and clinical applications. JAMA, 266, 1375-1383.
9. BENJAMIN D., KNOBLOCH T. J. and DAYTON M. A. (1992): Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10. Blood, 80, 1289-1298.
10. BERG D. J., KUHN R., RAJEWSKY K., MULLER W., MENON S., DAVIDSON N., GRUNIG G. and RENNICK D. (1995): Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest., 96, 2339-2347.
11. BETTELLI E., DAS M. P., HOWARD E. D., WEINER H. L., SOBEL R. A. and KUCHROO V. K. (1998): IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J. Immunol., 161, 3299-3306.
12. BLAZEVIC V., HEINO M., LAGERSTEDT A., RANKI A. and KROHN K. J. (1996): Interleukin-10 gene expression induced by HIV-1 Tat and Rev in the cells of HIV-1 infected individuals. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 13, 208-214.
13. BOGDAN C., VODOVOTZ Y. and NATHAN C. (1991): Macrophage deactivation by interleukin 10. J. Exp. Med., 174, 1549-1555.
14. BORGHI P., FANTUZZI L., VARANO B., GESSANI S., PUDDU P., CONTI L., CAPOBIANCHI M. R., AMEGLIO F. and BELARDELLI F. (1995): Induction of interleukin-10 by human immunodeficiency virus type 1 and its gp120 protein in human monocytes/macrophages. J. Virol., 69, 1284-1287.
15. BRIERE F., BRIDON J. M., CHEVET D., SOUILLET G., BIENVENU F., GURET C., MARTINEZ-VALDEZ H. and BANCHEREAU J. (1994): Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J. Clin. Invest., 94, 97-104.
16. BRIERE F., SERVET-DELPRAT C., BRIDON J. M., SAINT-REMY J. M. and BANCHEREAU J. (1994): Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J. Exp. Med., 179, 757-762.
17. BRIGINO E., HARAGUCHI S., KOUTSONIKOLIS A., CIANCIOLO G. J., OWENS U., GOOD R. A. and DAY N. K. (1997): Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc. Natl. Acad. Sci. USA, 94, 3178-3182.
18. BRODIE S. J., SASSEVILLE V. G., REIMANN K. A., SIMON M. A., SEHGAL P. K. and RINGLER D. J. (1994): Macrophage function in simian AIDS. Killing defects in vivo are independent of macrophage infection, associated with alterations in Th phenotype, and reversible with IFN-gamma. J. Immunol., 153, 5790-5801.
19. BUER J., LANOUE A., FRANZKE A., GARCIA C., VON BOEHMER H. and SARUKHAN A. (1998): Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J. Exp. Med., 187, 177-183.
20. BURDIN N., PERONNE C., BANCHEREAU J. and ROUSSET F. (1993): Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med., 177, 295-304.
21. CHAI J. G., BARTOK I., CHANDLER P., VENDETTI S., ANTONIOU A., DYSON J. and LECHLER R. (1999): Anergic T cells act as suppressor cells in vitro and in vivo. Eur. J. Immunol., 29, 686-692.
22. CHAKRABORTY A., BLUM R. A., CUTLER D. L. and JUSKO W. J. (1999): Pharmacoimmunodynamic interactions of interleukin-10 and prednisone in healthy volunteers. Clin. Pharmacol. Ther., 65, 304-318.
23. CHEHIMI J., STARR S. E., FRANK I., D'ANDREA A., MA X., MACGREGOR R. R., SENNELIER J. and TRINCHIERI G. (1994): Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J. Exp. Med., 179, 1361-1366.
24. CHERNOFF A. E., GRANOWITZ E. V., SHAPIRO L., VANNIER E., LONNEMANN G., ANGEL J. B., KENNEDY J. S., RABSON A. R., WOLFF S. M. and DINARELLO C. A. (1995): A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol., 154, 5492-5499.
25. CLERICI M., BALOTTA C., SALVAGGIO A., RIVA C., TRABATTONI D., PAPAGNO L., BERLUSCONI A., RUSCONI S., VILLA M. L., MORONI M. and GALLI M. (1996): Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection. Blood, 88, 574-579.
26. CLERICI M., HAKIM F. T., VENZON D. J., BLATT S., HENDRIX C. W., WYNN T. A. and SHEARER G. M. (1993): Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J. Clin. Invest., 91, 759-765.
27. CLERICI M., WYNN T. A., BERZOFSKY J. A., BLATT S. P., HENDRIX C. W., SHER A., COFFMAN R. L. and SHEARER G. M. (1994): Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J. Clin. Invest., 93, 768-775.
28. CREERY W. D., DIAZ-MITOMA F., FILION L. and KUMAR A. (1996): Differential modulation of B7-1 and B7-2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotype. Eur. J. Immunol., 26, 1273-1277.
29. CUA D. J., GROUX H., HINTON D. R., STOHLMAN S. A. and COFFMAN R. L. (1999): Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis. J. Exp. Med., 189, 1005-1010.
30. DAFTARIAN M. P., DIAZ-MITOMA F., CREERY W. D., CAMERON W. and KUMAR A. (1995): Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens. Clin. Diagn. Lab. Immunol., 2, 712-718.
31. DAFTARIAN P. M., KUMAR A., KRYWORUCHKO M. and DIAZ-MITOMA F. (1996): IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-α. J. Immunol., 157, 12-20.
32. DAI W. J., KOHLER G. and BROMBACHER F. (1997): Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10-deficient mice. J. Immunol., 158, 2259-2267.
33. DAVEY R. T. J., CHAITT D. G., PISCITELLI S. C., WELLS M., KOVACS J. A., WALKER R. E., FALLOON J., POLIS M. A., METCALF J. A., MASUR H., FYFE G. and LANE H. C. (1997): Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J. Infect. Dis., 175, 781-789.
34. DEL PRETE G., DE CARLI M., ALMERIGOGNA F., GIUDIZI M. G., BIAGIOTTI R. and ROMAGNANI S. (1993): Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J. Immunol., 150, 353-360.
35. DERKX B., MARCHANT A., GOLDMAN M., BIJLMER R. and VAN DEVENTER S. (1995): High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J. Infect. Dis., 171, 229-232.
36. DE WAAL MALEFRYT R., ABRAMS J., BENNETT B., FIGDOR C. G. and DE VRIES J. E. (1991): Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med., 174, 1209-1220.
37. DE WAAL MALEFRYT R., HAANEN J., SPITS H., RONCAROLO M. G., TE VELDE A., FIGDOR C., JOHNSON K., KASTELEIN R., YSSEL H. and DE VRIES J. E. (1991): Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med., 174, 915-924.
38. DIAZ-MITOMA F., KUMAR A., KARIMI S., KRYWORUCHKO M., DAFTARIAN M. P., CREERY W. D., FILION L. G. and CAMERON W. (1995): Expression of IL-10, IL-4 and interferon-gamma in unstimulated and mitogen-stimulated peripheral blood lymphocytes from HIV-seropositive patients. Clin. Exp. Immunol., 102, 31-39.
39. DING L., LINSLEY P. S., HUANG L. Y., GERMAIN R. N. and SHEVACH E. M. (1993): IL-10 inhibits, macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol., 151, 1224-1234.
40. DONNELLY R. P., DICKENSHEETS H. and FINBLOOM D. S. (1999): The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J. Interferon Cytokine Res., 19, 563-573.
41. ENK A. H., ANGELONI V. L., UDEY M. C. and KATZ S. I. (1993): Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol., 151, 2390-2398.
42. ESKDALE J., KUBE D., TESCH H. and GALLAGHER G. (1997): Mapping of the human IL-10 gene and further characterization of the 5′ flanking sequence. Immunogenetics, 46, 120-128.
43. FUCHS A. C., GRANOWITZ E. V., SHAPIRO L., VANNIER E., LONNEMANN G., ANGEL J. B., KENNEDY J. S., RABSON A. R., RADWANSKI E., AFFRIME M. B., CUTLER D. L., GRINT P. C. and DINARELLO C. A. (1996): Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin. Immunol., 16, 291-303.
44. + T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J. Immunol., 157, 798-805.
45. GENOVESE F., MANCUSO G., CUZZOLA M., BIONDO C., BENINATI C., DELFINO D. and TETI G. (1999): Role of IL-10 in a neonatal mouse listeriosis model. J. Immunol., 163, 2777-2782.
46. GERARD C., BRUYNS C., MARCHANT A., ABRAMOWICZ D., VANDENABEELE P., DELVAUX A., FIERS W., GOLDMAN M. and VELU T. (1993): Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med., 177, 547-550.
47. GO N. F., CASTLE B. E., BARRETT R., KASTELEIN R., DANG W., MOSMANN T. R., MOORE K. W. and HOWARD, M. (1990): Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J. Exp. Med., 172, 1625-1631.
48. GRAZIOSI C., PANTALEO G., GANTT K. R., FORTIN J. P., DEMAREST J. F., COHEN O. J., SEKALY R. P. and FAUCI A. S. (1994): Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV- infected individuals. Science, 265, 248-252.
49. GREENBERGER M. J., STRIETER R. M., KUNKEL S. L., DANFORTH J. M., GOODMAN R. E. and STANDIFORD T. J. (1995): Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol., 155, 722-729.
50. + T cells. J. Exp. Med., 184, 19-29.
51. GROUX H., COTTREZ F., ROULEAU M., MAUZE S., ANTONENKO S., HURST S., MCNEIL T., BIGLER M., RONCAROLO M. G. and COFFMAN R. L. (1999): A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol., 162, 1723-1729.
52. GRUNIG G., CORRY D. B., LEACH M. W., SEYMOUR B. W., KURUP V. P. and RENNICK D. M. (1997): Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med., 185, 1089-1099.
53. GUDMUNDSSON G., BOSCH A., DAVIDSON B. L., BERG, D. J. and HUNNINGHAKE G. W. (1998): Interleukin-10 modulates the severity of hypersensitivity pneumonitis in mice. Am. J. Respir. Cell Mol. Biol., 19, 812-818.
54. HAGENBAUGH A., SHARMA S., DUBINETT S. M., WEI S. H. Y., ARANDA R., CHEROUTRE H., FOWELL D. J., BINDER S., TSAO B., LOCKSLEY R. M., MOORE K. W. and KRONENBERG M. (1997): Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med., 185, 2101-2110.
55. HASKO G., VIRAG L., EGNACZYK G., SALZMAN A. L. and SZABO C. (1998): The crucial role of IL-10 in the suppression of the immunological response in mice exposed to staphylococcal enterotoxin B. Eur. J. Immunol., 28, 1417-1425.
56. HAZELZET J. A., KORNELISSE R. F., VAN DER Pouw KRAAN T. C., JOOSTEN, K. F., VAN DER VOORT E., VAN MIERLO G., SUUR M. H., HOP W. C., DE GROOT R. and HACK C. E. (1997): Interleukin 12 levels during the initial phase of septic shock with purpura in children: relation to severity of disease. Cytokine, 9, 711-716.
57. HEMPEL L., KORHOLZ D., BONIG H., SCHNEIDER M., KLEIN-VEHNE A., PACKEISEN J., MAUZ-KORHOLZ C. and BURDACH S. (1995): Interleukin-10 directly inhibits the interleukin-6 production in T-cells. Scand. J. Immunol., 41, 462-466.
58. HICKEY M. J., ISSEKUTZ A. C., REINHARDT P. H., FEDORAK R. N. and KUBES P. (1998): Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte endothelial cell interactions, and microvascular permeability during endotoxemia. Circ. Res., 83, 1124-1131.
59. HOWARD M., MUCHAMUEL T., ANDRADE S. and MENON S. (1993): Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med., 177, 1205-1208.
60. HUAUX F., LOUAHED J., HUDSPITH B., MEREDITH C., DELOS M., RENAULD J. C. and LISON D. (1998): Role of interleukin-10 in the lung response to silica in mice. Am. J. Respir. Cell Mol. Biol., 18, 51-59.
61. HUHN R. D., RADWANSKI E., O'CONNELL S. M., STURGILL M. G., CLARKE L., CODY R. P., AFFRIME M. B. and CUTLER D. L. (1996): Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood, 87, 699-705.
62. HUNTER C. A., ELLIS-NEYES L. A., SLIFER T., KANALY S., GRUNIG G., FORT M., RENNICK D. and ARAUJO F. G. (1997): IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J. Immunol., 158, 3311-3316.
63. ISHIDA H., HASTINGS R., KEARNEY J. and HOWARD M. (1992): Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J. Exp. Med., 175, 1213-1220.
64. JEANNIN P., LECOANET S., DELNESTE Y., GAUCHAT J. F. and BONNEFOY J. Y. (1998): IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol., 160, 3555-3561.
65. KELLY J. P. and BANCROFT G. J. (1996): Administration of interleukin-10 abolishes innate resistance to Listeria monocytogenes. Eur. J. Immunol., 26, 356-364.
66. KEYSTONE E., WHERRY J. and GRINT P. (1998): IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am., 24, 629-639.
67. KOLLMANN T. R., PETTOELLO-MANTOVANI M., KATOPODIS N. F., HACHAMOVITCH M., RUBINSTEIN A., KIM, A. and GOLDSTEIN H. (1996): Inhibition of acute in vivo human immunodeficiency virus infection by human interleukin 10 treatment of SCID mice implanted with human fetal thymus and liver. Proc. Natl. Acad. Sci. USA, 93, 3126-3131.
68. KOOTSTRA N. A. VAN 't WOUT A. B., HUISMAN H. G., MIEDEMA F. and SCHUITEMAKER H. (1994): Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J. Virol., 68, 6967-6975.
69. KORNELISSE R. F., HAZELZET J. A., SAVELKOUL H. F., HOP W. C., SUUR M. H., BORSBOOM A. N., RISSEEUW-APPEL I. M., VAN DER VOORT E. and DE GROOT R. (1996): The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J. Infect. Dis., 173, 1148-1156.
70. KUHN R., LOHLER J., RENNICK D., RAJEWSKY K. and MULLER W. (1993): Interleukin-10-deficient mice develop chronic enterocolitis. Cell, 75, 263-274.
71. KUMAR A., ANGEL J., DAFTARIAN M. P., PARATO K., CAMERON W. D., FILION L. and DIAZ-MITOMA F. (1998): Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. Clin. Exp. Immunol., 117, 84-91.
72. LANDAY A. L., CLERICI M., HASHEMI F., KESSLER H., BERZOFSKY J. A. and SHEARER G. M. (1996): In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J. Infect. Dis., 173, 1085-1091.
73. LEHMANN A. K., HALSTENSEN A., SORNES S., ROKKE O. and WAAGE A. (1995): High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect. Immun., 63, 2109-2112.
74. LI C., CORRALIZA I. and LANGHORNE J. (1999): A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect. Immun., 67, 4435-4442.
75. LI L., ELLIOTT J. F. and MOSMANN T. R. (1994): IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J. Immunol., 153, 3967-3978.
76. LIESCHKE G. J. and BURGESS A. W. (1992): Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N. Engl. J. Med., 327, 99-106.
77. LIN M. T., HINTON D. R., PARRA B., STOHLMAN S. A. and VAN DER VEEN R. C. (1998): The role of IL-10 in mouse hepatitis virus-induced demyelinating encephalomyelitis. Virology, 245, 270-280.
78. LLORENTE L., Zou W., LEVY Y., RICHAUD-PATIN Y., WIJDENES J., ALCOCER-VARELA J., MOREL-FOURRIER B., BROUET J. C., ALARCON-SEGOVIA D. and GALANAUD P. (1995): Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med., 181, 839-844.
79. MARCHANT A., ALEGRE M. L., HAKIM A., PIERARD G., MARECAUX G., FRIEDMAN G., DE GROOTE D., KAHN R. J., VINCENT J. L. and GOLDMAN M. (1995): Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J. Clin. Immunol., 15, 266-273.
80. MARCHANT A., DEVIERE J., BYL B., DE GROOTE D., VINCENT J. L. and GOLDMAN M. (1994): Interleukin-10 production during septicaemia. Lancet, 343, 707-708.
81. MASOOD R., ZHANG Y., BOND M. W., SCADDEN D. T., MOUDGIL T., LAW R. E., KAPLAN M. H., JUNG B., ESPINA B. M. and LUNARDI-ISKANDAR Y. (1995): Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood, 85, 3423-3430.
82. MEYAARD L., HOVENKAMP E., KEET I. P., HOOIBRINK B., DE JONG I. H., OTTO S. A. and MIEDEMA F. (1996): Single cell analysis of IL-4 and IFN-gamma production by T cells from HIV-infected individuals: decreased IFN-gamma in the presence of preserved IL-4 production. J. Immunol., 157, 2712-2718.
83. MOORE K. W., O'GARRA A., DE WAAL MALEFRYT R., VIEIRA P. and MOSMANN T. R. (1993): Interleukin-10. Annu. Rev. Immunol., 11, 165-190.
84. MULLER F., AUKRUST P., LIEN E., HAUG C. J. and FROLAND S. S. (1998): Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J. Infect. Dis., 177, 586-594.
85. MULLER F., AUKRUST P., NORDOY I. and FROLAND S. S. (1998): Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood, 92, 3721-3729.
86. MURRAY P. J., WANG L., ONUFRYK C., TEPPER R. I. and YOUNG R. A. (1997): T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J. Immunol., 158, 315-321.
87. MURRAY P. J. and YOUNG R. A. (1999): Increased antimycobacterial immunity in interleukin-10-deficient mice. Infect. Immun., 67, 3087-3095.
88. NORTH R. J. (1998): Mice incapable; of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp. Immunol., 113, 55-58.
89. PATTERSON B. K., CZERNIEWSKI M., ANDERSSON J., SULLIVAN Y., SU F., JIYAMAPA D., BURKI Z. and LANDAY A. (1999): Regulation of CCR5 and CXCR4 expression by type 1 and type 2 cytokines: CCR5 expression is downregulated by IL-10 in CD4-positive lymphocytes. Clin. Immunol., 91, 254-262.
90. RILEY J. K., TAKEDA K., AKIRA S. and SCHREIBER R. D. (1999): Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem., 274, 16513-16521.
91. ROMANO M. F., LAMBERTI A., PETRELLA A., BISOGNI R., TASSONE P. F., FORMISANO S., VENUTA S. and TURCO M. C. (1996): IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3- stimulated human peripheral T lymphocytes. J. Immunol., 156, 2119-2123.
92. ROULEAU M., COTTREZ F., BIGLER M., ANTONENKO S., CARBALLIDO J. M., ZLOTNIK A., RONCAROLO M. G. and GROUX H. (1999): IL-10 transgenic mice present a defect in T cell development reminiscent of SCID patients. J. Immunol., 163, 1420-1427.
93. ROUSSET F., GARCIA E., DEFRANCE T., PERONNE C., VEZZIO N., HSU D. H., KASTELEIN R., MOORE K. W. and BANCHEREAU J. (1992): Interleukin-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA, 89, 1890-1893.
94. SAVILLE M. W., TAGA K., FOLI A., BRODER S., TOSATO G. and YARCHOAN R. (1994): Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood, 83, 3591-3599.
95. SCHOLS D. and DE CLERCQ E. (1996): Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production. J. Virol., 70, 4953-4960.
96. + T cells. Annu. Rev. Immunol., 12, 635-673.
97. SHARMA V., KNOBLOCH T. J. and BENJAMIN D. (1995): Differential expression of cytokine genes in HIV-1 tat transfected T and B cell lines. Biochem. Biophys. Res. Commun., 208, 704-713.
98. SHERRY R. M., CUE J. I., GODDARD J. K., PARRAMORE J. B. and DIPIRO J. T. (1996): Interleukin-10 is associated with the development of sepsis in trauma patients. J. Trauma, 40, 613-616.
99. STANDIFORD T. J., STRIETER R. M., LUKACS N. W. and KUNKEL S. L. (1995): Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol., 155, 2222-2229.
100. STYLIANOU E., AUKRUST P., KVALE D., MULLER F. and FROLAND S. S. (1999): IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent anti-retroviral therapy. Clin. Exp. Immunol., 116, 115-120.
101. TAKANASKI S., NONAKA R., XING Z., O'BYRNE P., DOLOVICH J. and JORDANA M. (1994): Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J. Exp. Med., 180, 711-715.
102. TAN J. C., INDELICATO S. R., NARULA S. K., ZAVODNY P. J. and CHOU C. C. (1993): Characterization of interleukin-10 receptors on human and mouse cells. J. Biol. Chem., 268, 21053-21059.
103. VAN DER HEYDE H. C., PEPPER B., BATCHELDER J., CIGEL F. and WEIDANZ W. P. (1997): The time course of selected malarial infections in cytokine-deficient mice. Exp. Parasitol., 85, 206-213.
104. VAN, DER POOL T., MARCHANT A., BUURMAN W. A., BERMAN L., KEOGH C. V., LAZARUS D. D., NGUYEN L., GOLDMAN M., MOLDAWER L. L. and LOWRY S. F. (1995): Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol., 155, 5397-5401.
105. VAN DER POLL T., MARCHANT A., KEOGH C. V., GOLDMAN M. and LOWRY S. F. (1996): Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis., 174, 994-1000.
106. VAN DEVENTER S. J., ELSON C. O. and FEDORAK R. N. (1997): Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology, 113, 383-389.
107. VAZQUEZ-TORRES A., JONES-CARSON J., WAGNER R. D., WARNER T. and BALISH E. (1999): Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. Infect. Immun., 67, 670-674.
108. VIEIRA P., DE WAAL MALEFRYT R., DANG M. N., JOHNSON K. E., KASTELEIN R., FIORENTINO D. F., DEVRIES J. E., RONCAROLO M. G., MOSMANN T. R. and MOORE K. W. (1991): Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc. Natl. Acad. Sci. USA, 88, 1172-1176.
109. WAGNER E. F., HLEB M., HANNA N. and SHARMA S. (1998): A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. J. Immunol., 161, 1123-1131.
110. WALLEY K. R., LUKACS N. W., STANDIFORD T. J., STRIETER R. M. and KUNKEL S. L. (1996): Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect. Immun., 64, 4733-4738.
111. WANIDWORANUN C. and STROBER W. (1993): Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J. Immunol., 151, 6853-6861.
112. WEIMER R., ZIPPERLE S., DANIEL V., ZIMMERMANN R., SCHIMPF K. and OPELZ G. (1998): HIV-induced IL-6/IL-10 dysregulation of CD4 cells is associated with defective B cell help and autoantibody formation against CD4 cells. Clin. Exp. Immunol., 111, 20-29.
113. WEISSMAN D., OSTROWSKI M., DAUCHER J. A., GANTT K. R., BLAUVELT A., ALTMAN D., SHEN L., EHLER L., HOXIE J., GRINT P., KATZ S. I. and FAUCI A. S. (1998): Interleukin 10 decreases HIV plasma viral load: results of a phase I clinical trial. Abstract no. 37, Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, 71.
114. WYNN T. A., MORAWETZ R., SCHARTON-KERSTEN T., HIENY S., MORSE H. C., KUHN R., MULLER W., CHEEVER A. W. and SHER A. (1997): Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J. Immunol., 159, 5014-5023.
115. YANG X., GARTNER J., ZHU L., WANG S. and BRUNHAM R. C. (1999): IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J. Immunol., 162, 1010-1017.
116. YOO J., CHEN H., KRAUS T., HIRSCH D., POLYAK S., GEORGE I. and SPERBER K. (1996): Altered cytokine production and accessory cell function after HIV-1 infection. J. Immunol., 157, 1313-1320.
117. ZEIDLER R., EISSNER G., MEISSNER P., UEBEL S., TAMPE R., LAZIS S. and HAMMERSCHMIDT W. (1997): Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood, 90, 2390-2397.
118. ZHANG M., GONG J., IYER D. V., JONES B. E., MODLIN R. L. and BARNES P. F. (1994): T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J. Clin. Invest., 94, 2435-2442.
119. ZHENG X. X., STEELE A. W., NICKERSON P. W., STEURER W., STEIGER J. and STROM T. B. (1995): Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J. Immunol., 154, 5590-5600.